Gilead (GILD) Q1 2026 Earnings Call Transcript

Gilead reported Q1 total product sales of $6.9 billion, up 5% year over year, and raised 2026 revenue guidance to $30.0 billion-$30.4 billion, driven by HIV, oncology, and liver disease growth. HIV sales rose 10% to $5.0 billion, Yes2Go sales jumped 72% sequentially to $166 million with full-year guidance lifted to $1 billion, and Trodelvy gained 37% year over year to $402 million. The company also highlighted major pipeline and M&A progress, including the closed Arcellx deal, pending Oral Medicines and Tubulis acquisitions, and up to four launches plus multiple regulatory catalysts in 2026.

Analysis

The core signal is not the headline beat; it’s that Gilead has regained pricing power in a business the market had implicitly treated as mature. The mix shift toward prevention and away from legacy drag is expanding gross margin while the company simultaneously resets the growth runway through multiple launch layers, which should keep the multiple from compressing even as near-term earnings are clouded by deal accounting. The market is likely underappreciating how much of the 2026 “EPS loss” is non-cash/transactional noise versus an actual deterioration in operating earnings power.

The most important second-order effect is competitive: the new long-acting HIV prevention franchise can force rivals into a much more expensive commercial contest because the battle is no longer just efficacy, it is access, persistence, and DTC-driven habit formation. If the company sustains early adherence and persistence, the prevention business becomes structurally stickier than treatment, which should support a longer duration revenue annuity and reduce the probability that generic/preferred-formulary pressure erodes the HIV moat before 2030. That also makes the oral/long-acting pipeline more valuable because it converts the current installed base into a launchpad for successive line extensions.

The oncology and cell-therapy pieces are more interesting as option value than as 2026 P&L drivers. The real catalyst path is a sequence of de-risking events over the next 6-18 months: regulatory decisions, then label expansions, then earlier-line trial reads; if even two of those go right, the market will have to re-rate Gilead as a platform company rather than a single-franchise cash generator. Conversely, the main failure mode is execution dilution: integrating too many assets at once could slow launches or obscure signal quality, especially if one of the major readouts underwhelms and forces the market to question the acquisition binge.

Consensus is probably too focused on the accounting drag and not focused enough on the fact that this is one of the few large-cap biopharmas with both near-term commercial acceleration and a credible multi-year product cadence. The stock can work even if some pipeline assets disappoint, but the asymmetry improves materially if the HIV prevention trajectory holds and one of the large oncology assets converts into a credible 2027-2028 growth leg. In other words, this is less a single-event story and more a compounding optionality story with a still-strong cash engine underneath.

Key Decisions for Investors

• Long GILD common into the next 3-6 months; use any post-guidance-volatility dip as entry, since the non-GAAP guide is effectively intact ex-deal accounting and the revenue reset is only $400M while operating momentum is improving.
• Buy GILD Jan-2027 calls / call spreads to express the 12-18 month re-rating thesis; risk/reward is attractive if HIV prevention persistence holds and one or more 2026 catalysts de-risk the pipeline.
• Pair trade: long GILD vs short a basket of higher-multiple large-cap pharma names with weaker organic growth; GILD has better near-term revenue slope plus multiple launch catalysts, while the short leg should underperform if the market rewards self-help and pipeline cadence.
• Tactically sell downside puts only after catalyst windows on GILD; implied volatility should remain elevated around regulatory dates, but the cash franchise and buyback/dividend support should cap deep drawdowns absent a pipeline shock.
• Monitor ACLX post-close and consider a relative long in ACLX vs other cell-therapy names if anitocel launch planning accelerates; the market may rerate differentiated CAR-T safety earlier than the broader oncology pipeline gets credit for.